New methodologies in pathologic analysis of tissue specimens have contributed to improvements in the diagnosis of infectious agents, dystrophies, degenerations, and neoplasms, as well as to the classification of neoplasms, particularly the non-Hodgkin lymphomas and sarcomas. Refinements in immunohistochemical (IHC) staining and in flow cytometric, molecular genetic, and cytogenetic techniques lead to more accurate diagnoses and to more precise identification of biomarkers of value in risk stratification, prognostication, and targeted therapeutics.
If special studies are anticipated, the ophthalmic surgeon is responsible for consulting with the pathologist prior to the procedure and then appropriately obtaining and submitting tissue for evaluation. See Table 3-1 for a checklist of important considerations when submitting tissue for pathologic consultation.
Excerpted from BCSC 2020-2021 series: Section 4 - Ophthalmic Pathology and Intraocular Tumors. For more information and to purchase the entire series, please visit https://www.aao.org/bcsc.